CANDIDATES FOR THERAPY BONE CONDUCTION HEARING THERAPY
The Alpha 2 MPO ePlus™ bone conduction hearing system is suitable for patients with conductive hearing loss, mixed hearing loss, and single-sided deafness. The bone-anchored hearing system (BAHS) is comprised of the titanium encased magnetic implant,1 the Attract™ magnetic spacer, and the Alpha 2 MPO sound processor.
The magnetic implant is the smallest on the market and lies completely under the skin.1,2 It is surgically placed and is indicated for patients 5 years and older. The Alpha 2 MPO ePlus™ currently boasts the lowest profile implant on the market and is a safe alternative to more intrusive implants.3 Pediatric patients (≤ 5 years old) and those not wanting to undergo surgery can still experience improved hearing by wearing the sound processor on a softband or headband.
The Alpha 2 MPO ePlus™ magnetic bone conduction hearing device is indicated for use among those with a conductive or mixed hearing loss where the bone conduction thresholds are ≤ 45 dB. Ideal candidates will have bone conduction thresholds of ≤ 35 dB for the indicated ear.2 Patients with bone conduction thresholds greater than 35 dB should be carefully evaluated for the system.
For patients with single-sided deafness (SSD) the better hearing ear should have normal hearing (thresholds ≤ 20 dB). Sound is received by the Alpha 2 MPO ePlus™ sound processor worn on the poorer hearing side and is then transferred to the better functioning cochlea. This configuration reduces the head shadow effect.
Siegert R., M.D., Semi-implantable transcutaneous bone conduction hearing device with fitting on the day of surgery. Presented at the 29th Politzer Society Meeting, Antalya, Turkey, Nov. 2013.
Centric A and Chennupati, SK, Abutment-free bone-anchored hearing devices in children: Initial results and experience - International Journal of Pediatric Otolaryngology 2014.
Siegert R and Kanderske J. A New Semi-Implantable Transcutaneous Bone Conduction Device: Clinical, Surgical, and Audiologic Outcomes in Patients with Congenital Ear Canal Atresia. Otology & Neurotology 2013, 34:927-934.